Evidence map›Paper›PMID 42244638›Full record

ArticlebioRxiv : the preprint server for biology2026

Ecology and engineering to modify the bile acid output of a defined microbial community.

Xianfeng Zeng, Xiandong Meng, Allison M Weakley, Kelsey E Jarrett, Steven Higginbottom, Eugenell Mae Lopez, Ashley V Cabrera, Ira J Gray, Brian C DeFelice, Masahiko Terasaki and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xianfeng ZengDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-9593-3388
Xiandong MengDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Allison M WeakleyChEM-H Institute, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0001-6694-6964
Kelsey E JarrettDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.ORCID 0000-0001-5358-8280
Steven HigginbottomChEM-H Institute, Stanford University, Stanford, CA 94305, USA.
Eugenell Mae LopezChEM-H Institute, Stanford University, Stanford, CA 94305, USA.
Ashley V CabreraChEM-H Institute, Stanford University, Stanford, CA 94305, USA.
Ira J GrayChan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Brian C DeFeliceChan Zuckerberg Biohub, San Francisco, CA 94158, USA.
Masahiko TerasakiDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Rochelle LaiDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Madelaine Brearley-SholtoDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Aishan ZhaoDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-9010-7981
Kerrigan R HallDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Mikhail LeviaChEM-H Institute, Stanford University, Stanford, CA 94305, USA.
Jeanette ArreolaChEM-H Institute, Stanford University, Stanford, CA 94305, USA.
Thomas Q de Aguiar VallimDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Michael A FischbachDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-3079-8247

Funding

Dietary and Microbial Reprogramming of Intestinal Microbiota-Produced MetabolitesR01DK101674 · NIDDK · STANFORD UNIVERSITY · PI FISCHBACH, MICHAEL ANDREW, MEYER, TIMOTHY W · 2014 to 2024
$6.5M
NIDDK NIH HHS R01 DK101674
6 · The paper itself

Abstract

The bile acid pool, which is synthesized collaboratively by the host and its microbiome, impacts metabolism, immunity, and disease risk. Targeted microbiome interventions could in principle reshape the bile acid pool for therapeutic benefit, but practical strategies remain elusive. In the course of screening a complex defined community for metabolic phenotypes by dropping out individual strains, we observed that several of the single-strain dropout communities had markedly increased deoxycholic and lithocholic acid levels and a larger bile acid pool. In each of these communities, a second strain-

Identifiers

PMID42244638
PMCPMC13232296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.